Annual report pursuant to Section 13 and 15(d)

Summary of significant accounting policies (Tables)

v2.4.0.8
Summary of significant accounting policies (Tables)
12 Months Ended
Jul. 31, 2014
Accounting Policies [Abstract]  
Schedule Of Segment Revenue And Revenue Percentage [Table Text Block] The following table summarizes the Clinical Lab segment’s net revenues and revenue percentages by revenue category:

    Years Ended July 31,  
    2014     2013     2012    
Revenue category    Amount     %      Amount     %      Amount     %    
Third-party payers   $   29,509       50     $   26,014       47     $   29,616       50    
Medicare     12,815       22       12,497       22       12,658       21    
Patient self-pay     11,204       19       12,172       22       11,895       20    
HMO’s     5,161       9       5,206       9       5,234       9    
Total   $ 58,689       100 %   $ 55,889       100 %   $ 59,403       100 %  
                                                     
Schedule Of Accounts Receivable By Segment [Table Text Block] The following is a table of the Company’s net accounts receivable by segment.

    July 31, 2014     July 31, 2013  
Net accounts receivable by segment   Amount     %     Amount      %  
Clinical Labs (by billing category)                                
Third party payers   $ 3,499       46     $ 3,395       46  
Patient self-pay     2,193       29       2,696       37  
Medicare     1,558       21       930       13  
HMO’s     280       4       300       4  
Total Clinical Labs     7,530       100 %     7,321       100 %
                                 
Total Life Sciences     4,940               4,967          
Total accounts receivable – net   $ 12,470             $ 12,288          
Schedule of Allowance for Doubtful Accounts Receivable [Table Text Block] Changes in the Company’s allowance for doubtful accounts are as follows:

    July 31, 2014     July 31, 2013  
Beginning balance   $ 2,707     $ 3,273  
Provision for doubtful accounts     3,063       4,496  
Write-offs     (3,628 )     (5,062 )
Ending balance   $ 2,142     $ 2,707  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] The following table sets forth the computation of basic and diluted net loss per share for the years ended July 31:

    2014     2013     2012  
Net loss   $ (9,977 )   $ (18,237 )   $ (39,269 )
                         
Weighted-average common shares outstanding - Basic     42,561       39,607       38,798  
Add: effect of dilutive stock options and restricted stock                  
Weighted-average common shares outstanding - Diluted     42,561       39,607       38,798  
                         
Net loss per share:                        
Basic and diluted   $ (0.23 )   $ (0.46 )   $ (1.01 )
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statement of operations for the years ended July 31:

    2014     2013     2012  
Cost of clinical laboratory services   $ 9     $ 10     $ 10  
Research and development     1       2       4  
Selling, general and administrative     584       533       705  
    $ 594     $ 545     $ 719